Cargando…

Evaluation of Combination Strategies for the A(2A)R Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model

BACKGROUND: Adenosine receptor type 2 (A(2A)R) inhibitor, AZD4635, has been shown to reduce immunosuppressive adenosine effects within the tumor microenvironment (TME) and to enhance the efficacy of checkpoint inhibitors across various syngeneic models. This study aims at investigating anti-tumor ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voronova, Veronika, Peskov, Kirill, Kosinsky, Yuri, Helmlinger, Gabriel, Chu, Lulu, Borodovsky, Alexandra, Woessner, Richard, Sachsenmeier, Kris, Shao, Wenlin, Kumar, Rakesh, Pouliot, Gayle, Merchant, Melinda, Kimko, Holly, Mugundu, Ganesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962275/ https://www.ncbi.nlm.nih.gov/pubmed/33737925 http://dx.doi.org/10.3389/fimmu.2021.617316

Ejemplares similares

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
por: Lim, Emerson A., et al.
Publicado: (2022)

Small molecule AZD4635 inhibitor of A(2A)R signaling rescues immune cell function including CD103(+) dendritic cells enhancing anti-tumor immunity
por: Borodovsky, Alexandra, et al.
Publicado: (2020)

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis
por: Shulgin, Boris, et al.
Publicado: (2020)

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model
por: Kosinsky, Yuri, et al.
Publicado: (2018)

Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?
por: Voronova, Veronika, et al.
Publicado: (2017)

Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis
por: Voronova, Veronika, et al.
Publicado: (2020)

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study
por: Azarov, Ivan, et al.
Publicado: (2019)

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
por: Helmlinger, Gabriel, et al.
Publicado: (2019)

A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings
por: Voronova, Veronika, et al.
Publicado: (2020)

Iodine nutrition status and thyroid autoimmunity during pregnancy: a cross-sectional study of 4635 pregnant women
por: Chen, Xiao, et al.
Publicado: (2022)

A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies
por: Shulgin, Boris, et al.
Publicado: (2016)

Cycle Network Model of Prostaglandin H Synthase-1
por: Goltsov, Alexey, et al.
Publicado: (2020)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab
por: Gavrilov, Sergey, et al.
Publicado: (2020)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics
por: Zhudenkov, Kirill, et al.
Publicado: (2022)

We need to bring R0 < 1 to treat cancer too
por: Srikrishna, Devabhaktuni, et al.
Publicado: (2021)

Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
por: Voronova, Veronika, et al.
Publicado: (2022)

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study
por: Någård, Mats, et al.
Publicado: (2023)

Improving Realism in Clinical Trial Simulations via Real‐World Data
por: Kimko, Holly, et al.
Publicado: (2017)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
por: Hamilton, Erika P., et al.
Publicado: (2023)

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2023)

Evaluation of therapeutic strategies targeting BCAA catabolism using a systems pharmacology model
por: Voronova, Veronika, et al.
Publicado: (2022)

Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is Essential
por: Rekić, Dinko, et al.
Publicado: (2020)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
por: Bauer, Todd M., et al.
Publicado: (2023)

Systems Modeling to Quantify Safety Risks in Early Drug Development: Using Bifurcation Analysis and Agent-Based Modeling as Examples
por: Pin, Carmen, et al.
Publicado: (2021)

Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition
por: Wang, Hanwen, et al.
Publicado: (2023)

Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition
por: Wang, Hanwen, et al.
Publicado: (2023)

Agent Based Modeling of Human Gut Microbiome Interactions and Perturbations
por: Shashkova, Tatiana, et al.
Publicado: (2016)

Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients
por: Salem, Ahmed M., et al.
Publicado: (2023)

A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor–Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy
por: Gong, Chang, et al.
Publicado: (2021)

Quantifying Intratumoral Heterogeneity and Immunoarchitecture Generated In-Silico by a Spatial Quantitative Systems Pharmacology Model
por: Nikfar, Mehdi, et al.
Publicado: (2023)

AZD-1222: Guillain-Barre syndrome
Publicado: (2021)

AZD-1222: Rhabdomyolysis: case report
Publicado: (2022)

AZD-1222: Polyarthralgia: case report
Publicado: (2021)

Azd-1222: Myelitis: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5mm1q9ibd2210oi3s5udftuta8